Dosing & Uses
Ehlers-Danlos Syndrome
Pending FDA for treatment of vascular Ehlers-Danlos syndrome (vEDS)
Next:
Pharmacology
Mechanism of Action
Theorized to provide clinical benefit for vEDS by promoting normal collagen synthesis in blood vessels; may also shift pressure load away from vessels most prone to dissection and rupture
Beta1 receptor antagonist, but elicits partial agonist effects on beta2 receptors; it is also a weak alpha2 receptor antagonist
Lowers blood pressure in patients with hypertension, but not in normotensive patients
Previous
Next:
Images
No images available for this drug.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
